Summary:
Summit Dermatology is conducting a prospective phase 1 study to test the safety and effectiveness of VTP-38543 topical treatment in adult patients with eczema.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Be diagnosed with eczema
•
Be willing to comply with study visits
Qualified Participants May Receive:
The study drug at no cost, physical exam, vital signs, lab/blood work and compensation for their time.